Related Experiment Video

Updated: May 31, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against

Daniel Gioeli1, Winfried Wunderlich, Judith Sebolt-Leopold

  • 1Department of Microbiology, PO Box 800734, University of Virginia Health System, Charlottesville, VA 22908, USA. dgg3f@virginia.edu

Molecular Cancer Therapeutics
|June 30, 2011
PubMed

Insights

Targeted therapies for solid tumors show improved efficacy when combined. Identifying compensatory pathways upregulated by single-agent treatment, like MEK inhibition, enables rational drug combinations for prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Single-agent targeted therapies often yield suboptimal outcomes in solid tumors.
  • Rational drug combinations are crucial for enhancing therapeutic efficacy.
  • Understanding compensatory signaling pathways is key to designing effective combination strategies.

Purpose of the Study:

  • To identify upregulated signaling pathways in response to MAP/ERK kinase (MEK) inhibitor treatment in prostate cancer.
  • To guide the rational combination of targeted drugs based on identified compensatory pathways.
  • To investigate synergistic effects of combined targeted therapies in prostate cancer models.

Main Methods:

  • Gene array and protein phosphorylation analysis were used to map signaling pathway alterations.
  • Prostate cancer xenografts were treated with the MEK inhibitor PD325901.
  • In vitro cell growth and survival assays were performed to evaluate drug combinations.

Main Results:

  • Treatment with PD325901 upregulated components of the extracellular signal-regulated kinase (ERK) pathway, as well as IKK, hedgehog, and phosphoinositide 3-kinase/Akt/mTOR pathways.
  • Combinations of PD325901 with inhibitors of these upregulated pathways demonstrated synergistic growth inhibition.
  • Individual drug treatments were less effective than the rationally designed combinations.

Conclusions:

  • Identification of compensatory signaling pathways provides a basis for rational combination therapy design.
  • Combined targeted therapies targeting MEK and identified compensatory pathways offer a promising strategy for prostate cancer treatment.
  • This approach can overcome resistance mechanisms and improve treatment outcomes in solid tumors.

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...